Active	Status	Sponsor type	Region	Phase	Filter
32 Active 13 Inactive 45 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liang, Jing
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	Completed	3	275	RoW	GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant	Genor Biopharma Co., Ltd.	Locally Advanced or Metastatic Breast Cancer	12/22	03/24
NCT04507750: Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer	Recruiting	N/A	40	RoW	Camrelizumab, apatinib mesylate	Qianfoshan Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd.	Immune Checkpoint Inhibition	08/21	08/22
NCT04997590: Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Healing	Recruiting	N/A	40	RoW	Umbilical cord blood mononuclear cells, Staphylococcal Enterotoxin C	Qianfoshan Hospital, Shandong Qilu Stem Cells Engineering Co., Ltd.	Bone Nonunion	12/21	12/22
Mendez, Katherin
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus	Recruiting	3	406	Europe, Canada, Japan, US, RoW	Ianalumab, VAY736, Placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Systemic Lupus Erythematosus	01/27	04/29
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
ROBUST, NCT05675046: Multicenter Prospective Trial of Office-based Carpal Tunnel Release With Ultrasound Guidance	Active, not recruiting	N/A	149	US	Ultrasound Guided Carpal Tunnel Release (CTR-US), UltraGuideCTR	Sonex Health, Inc.	Carpal Tunnel Syndrome, CTS	09/23	12/25
Bardakcioglu, Ovunc
NCT04651764: Transanal Resection of Rectal Lesions With the ColubrisMX ELS System	Terminated	N/A	26	US	ColubrisMX Endoluminal Surgical (ELS) System	ColubrisMX	Rectal Adenoma, Rectal Polyp, Rectal Lesion	06/21	06/21
Rosenkranz, Sara
NCT04277741: Long-term Consumption of Resistant Starch Type-4 (RS4)	Withdrawn	N/A	50	US	RS4 bar, Control bar	Kansas State University, MGP Ingredients, Inc.	Cholesterol, Elevated, Overweight or Obesity	06/23	06/23
Pistorio, Ashley
ROBUST, NCT05675046: Multicenter Prospective Trial of Office-based Carpal Tunnel Release With Ultrasound Guidance	Active, not recruiting	N/A	149	US	Ultrasound Guided Carpal Tunnel Release (CTR-US), UltraGuideCTR	Sonex Health, Inc.	Carpal Tunnel Syndrome, CTS	09/23	12/25
Mendez, Katherine
ROBUST, NCT05675046: Multicenter Prospective Trial of Office-based Carpal Tunnel Release With Ultrasound Guidance	Active, not recruiting	N/A	149	US	Ultrasound Guided Carpal Tunnel Release (CTR-US), UltraGuideCTR	Sonex Health, Inc.	Carpal Tunnel Syndrome, CTS	09/23	12/25
Kawi, Jennifer
No trials found
Beck, Victor DY
No trials found
Lee, Hyunhwa
No trials found
Bengochea, Alain
No trials found
Morgan, Joseph
No trials found
Ho, Kai Yu
No trials found
Bernabae, Victoria
No trials found